I’m incredibly honored to receive the Women Entrepreneur Award at Hospex India Medical Expo 2024 as the founder of Augsidius Health. This recognition is a testament to the dedication of our team and our shared vision to enhance patient-centric care through innovative #healthcare AI solutions. I’m deeply grateful for the opportunity to contribute to the #futureofhealthcare and excited for the journey ahead as we work to make a lasting impact. A heartfelt thank you to everyone who has supported us along the way!
Congratulations to us! @Dr. Meghnath Reddy @Kushal Kulle
#healthcareAI #healthtech #AIinHealthcare #startup #womenentrepreneur #hospex

Congratulations ! Women Entrepreneur Award at Hospex India Medical Expo 2024 as the founder of Augsidius Health Akhila Kosuru

📣 Introducing Divaux Media Company! 🎬

Your new partner for innovative content delivery. Our mission is to blend creativity with technology to tell visual stories that inspire and engage.

At Divaux Media, we specialise in:

🎥 Content Creation
📱 Video Production
🌐 Strategic Content Delivery

We have worked with doctors to expand their audience reach from few hundred followers to over 200K subscribers in Instagram and Youtube organically. If you would like to leverage the power of social media to build an audience for yourself organically, get in touch with us. Our passionate team is dedicated to delivering high-quality content that resonates with audiences worldwide.

Mail us at harold.paul@divaux.com

Meet the woman behind the Dseide Healthcare Networking Platform!

It was an incredible experience at Hospex 2024, and a big thanks to Soumya for successfully orchestrating a collaboration between the Hospex Healthcare Expo and naming Dseide as the community enabler, standing alongside industry giants. This event propelled our network from 350+ healthcare companies to 400+, with 50+ new companies joining us in just 2 days!

Exciting times ahead for Dseide and the healthcare industry. Looking forward to fostering more innovation and connections!"

#Dseide #Hospex2024 #HealthcareNetworking #CommunityEnabler #HealthcareInnovation

We are thrilled to announce the publication of another case report featuring our innovative PriciGuide® System in the Journal of Conservative Dentistry and Endodontics! 🎉

This case, a collaboration between Dr. Shabnam Md, Dr. Varun Prabhuji and Dr. Neevika Singh, highlights the precision and efficiency of the PriciGuide® system in advanced endodontic therapy, setting new standards in minimally invasive dental care.

https://journals.lww.com/jcde/fulltext/2024/27100/precision_in_endodontic_therapy_by_novel_guided.16.aspx

Stay tuned for more cutting-edge innovations from Roots to Cusps®!

#Endodontics #PriciGuide #DentalInnovation #RootsToCusps

Take a look at the highlights from Dseide at Hospex Healthcare Expo 2024! Where innovation meets opportunity, Hospex 2024 was filled with dynamic interactions, exciting pitches, and insightful conferences. Here's a glimpse into our journey at the event, showcasing the power of collaboration and cutting-edge healthcare advancements.

Hospex India Ishika Coordinator
DILIP K [PreranaMCoordinator] Soumya TS

#Hospex2024 #HealthcareInnovation #DseideAtHospex #HealthcareExpo #MedicalTech #InnovationInHealthcare #HealthcareCommunity #NetworkingInHealthcare #HealthcareConferences #HealthTech #HealthcarePitches #MedicalExpo2024 #HealthcareCollaboration

Congratulation Akhila Kosuru

Exciting news in the world of pediatric health! Researchers have made significant progress in developing a vaccine against Respiratory Syncytial Virus (RSV), a common virus that causes severe respiratory illness in young children.

Pfizer's vaccine, called ABRYSVO, has shown promising results in clinical trials, particularly among immunocompromised adults and older adults . In fact, the FDA has already approved ABRYSVO for preventing lower respiratory tract disease caused by RSV in individuals 60 years of age or older, as well as for pregnant individuals to help protect infants from birth up to six months of age .

Key Benefits of ABRYSVO:
*Prevents lower respiratory tract disease caused by RSV in individuals 60 years of age or older.

*Helps protect infants from birth up to six months of age when administered to pregnant individuals.

*Shows strong neutralizing responses against both RSV-A and RSV-B subtypes.

Ongoing Research:
Pfizer has initiated a clinical trial evaluating ABRYSVO in children ages two to less than 18 years who are at higher risk for RSV disease . This is a significant step forward in protecting younger populations from the devastating effects of RSV.
These breakthroughs offer new hope for vulnerable populations, and we can expect even more advancements in the fight against RSV in the coming years!

Better Health: Revolutionizing Healthcare for a Better Tomorrow

Stay Tuned for the Founders' Podcast!
Better healthcare founders' upcoming podcast will dive deep into the vision, journey, and groundbreaking innovations that make Better Health a leader in healthcare transformation. Be sure to tune in to hear the stories behind the scenes, discover how they are changing lives, and get inspired by future-forward approach to wellness.
Better Healthcare

#BetterHealth #HealthcareInnovation #WellnessRevolution #EmpowerYourHealth #FutureOfHealthcare